Evaluation of triazine-based lipid nanoparticle (LNP) formulations for mRNA

delivery in a mouse model

College of Pharmacy

Nabilah Ibnat¹, Abdullah Al-Masud², Timothy Funk³, Dlovan D. Mahmood ⁴, Jeremy P. Wood⁴, Vincent J. Venditto¹

¹Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Kentucky, USA / ² Department of Ophthalmology and Vision Science, College of Medicine, University of Kentucky, Kentucky, Kentucky, Kentucky, USA/ ³Department of Chemistry, Gettysburg College, Pennsylvania, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Kentucky, Kentucky, USA/ ³Department of Chemistry, Gettysburg College, Pennsylvania, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, USA/ ⁴Saha Cardiovascular Research Center, College of Medicine, USA/ ⁴Saha Cardiovascular Research Center,

ABSTRACT

Lipid nanoparticles (LNPs) are the most advanced delivery systems for messenger RNA (mRNA). Recent clinical trials of mRNA-LNP therapeutics have focused on vaccines, liver diseases, and cancer. However, safe and effective delivery of mRNA to the lungs is still a formidable challenge [1]. To meet the critical need, the primary component of LNP, called ionizable lipids, can be engineered to target specific tissues. In this study, we designed a library of triazine-based (TZ) ionizable lipids with cyanuric chloride and dialkyl amines [2] that are capable of systemic mRNA delivery to the lung tissues. The TZ-based LNPs specifically delivered Fluc mRNA to the lungs following intravenous injections in mice. Furthermore, evaluation for blood toxicity or clotting [3,4] in the tissue is still under investigation. Our findings highlight the potential of TZ lipids for safe pulmonary delivery of mRNA, opening therapeutic avenues for lung-related diseases.

Triazine lipids MRNA-LNP Formulation treatment Clotting Activity Tissue histology In vivo/ex vivo imaging

OBJECTIVE


To evaluate mRNA transfection efficiency of Triazine (TZ) lipids both in vitro and in vivo for fine-tuning its biocompatibility in the blood and tissue of a mouse model.

CONCLUSION AND FUTURE DIRECTIONS

Triazine (TZ) lipids demonstrated lung-specific mRNA expression in mice with minimal liver expression, unlike ALC-0315. Also, compared to DOTAP cationic lipid, TZ lipids demonstrate reduced blood clotting and tissue damage in mouse lungs. For the future, the planned experiments are to test


- Types of pulmonary cells transfected by TZ lipid formulations
- Assess TZ transfection efficiency in a mouse disease model
- Continue tissue staining to further evaluate blot clotting in the mouse lung.

RESULTS




Physico-chemical characterization

TZ lipid formulations (F7, F8, F10) optimized by design of experiment (DOE) approach. DOTAP and ALC formulations based on literature reports.



TZ lipids exhibited similar formulation characteristics compared to the industry standard (ALC-0315, Pfizer).


In vivo transfection efficiency





TZ lipids have improved EE%, similar toxicity, and pKa values greater than ALC-0315.

In vitro HEK-293 transfection efficiency B. 250000 of GFP (+ve) cells 30 200000 150000 100000 50000 F10 ALC 0315 F8 F10 ALC 0315 TZ lipids showed higher % of 후 60000-GFP mRNA transfection and enhanced mean fluorescence intensity compared to ALC-0315 control.

F10 ALC 0315









TZ lipids demonstrated lung-specific expression of Fluc mRNA in mouse; with 100-fold enhanced lung/liver in comparison to ALC-0315, and similar ratio as DOTAP lipid.

Calibrated Automated Thrombin (CAT) Assay in ex vivo plasma from naïve mice To up per proposition of the p




TZ lipid F7, showed similar lag time and Thrombin-antithrombin plasma (TAT) concentration as ALC-0315 control.

Evaluation of tissue damage and blood clotting in lung tissues by Masson's Trichrome staining



TZ lipids and DOTAP display tissue damage in the lung of mice compared to ALC-0315 and control untreated mice.

METHODS



REFERENCES

- 1.Omo-Lamai,et al., "Physicochemical Targeting of Lipid Nanoparticles to the Lungs Induces Clotting: Mechanisms and Solutions." 2023.
- http://biorxiv.org/lookup/doi/10.1101/2023.07.21.550080
- 2. Nardo, David, et.al., "Cyanuric Chloride as the Basis for Compositionally Diverse Lipids." 2021. RSC Advances 11 (40): 24752–61.
- 3. Giesen, P. L. A., et.al., "Calibrated Automated Thrombogram II: Removing Barriers for Thrombin Generation Measurements." 2021. *Thrombosis Journal* 19 (1): 60.
- 4. Murphy, Claire A., et. al., 2022. "The Role of the Calibrated Automated Thrombogram in Neonates: Describing Mechanisms of Neonatal Haemostasis and Evaluating Haemostatic Drugs." *European Journal of Pediatrics* 181 (1): 23–33.

ACKNOWLEDGEMENTS

This project is supported with grants from KSCHIRT (24-15) and the NIH (U01HL152392, R01HL152081). VJV is also supported by grants from the NIH (R01NS116068, R01NS126228) and an NIH Center for Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation (CPRI, P20GM130456).



